İnaktive Poliovirüs ve Oral Poliovirüs Aşılarının Karşılaştırılması

Yıl 2013, , 1 - 5, 01.06.2013

Hüseyin Anıl Korkmaz Adem Aydın Belgin Ünal

https://doi.org/10.4274/Jcp.11.01

Öz

Giriş: Bu çalışmada inaktive poliovirüs aşısı İPV ve oral poliovirüs OPV aşılarının uygulandıkları 2., 4., 6. ve 18. aylarda oluşturdukları sistemik yan etkiler ve ateş reaksiyonları açısından karşılaştırılması amaçlanmıştır.Gereç ve Yöntem: Çalışma grubunu 2003 ile 2008 yılları arasında 2, 4, 6 ve 18 aylıkken İPV ve OPV uygulandıktan sonra değerlendirilen 1634 sütçocuğu oluşturmuştur. Tüm aileler çocuklarında oluşan sistemik ve ateş reaksiyonları ile ilgili yan etkileri araştırmacıya bildirmiştir.Bulgular: OPV uygulanmasından sonra oluşan sistemik ve ateş reaksiyonları İPV’ye göre anlamlı derecede yüksek bulundu sırasıyla %2,33’e karşılık %1,12 ve %5,2’ye karşılık %2,8; p

Anahtar Kelimeler

İnaktive poliovirüs aşısı, oral poliovirüs aşısı, aşılar, süt çocukları, yan ekiler

Comparison of Inactivated and Oral Poliovirus Vaccines

Öz

In tro duc ti on: The aim of this study was to compare the rates of systemic and fever reactions of inactivated poliovirus vaccine IPV and oral poliovirus vaccine OPV at 2, 4, 6 and 18 months of age.Materials and Methods: The study population was made up of 1634 infants at 2, 4, 6, and 18 months of age who had received IPV and OPV vaccines between 2003 and 2008. All parents reported systemic and fever adverse events to the investigator.Results: Systemic and fever reactions were more commonly observed in infants received OPV vaccines than those received IPV vaccines 2.33% vs. 1.12% and 5.2% vs. 2.8%; p

Anahtar Kelimeler

Inactivated poliovirus vaccine, oral poliovirus vaccine, vaccines, infants, adverse events

Kaynakça

• 1. Poliomyelitis prevention: revised recommendations for use of inactivated and live oral poliovirus vaccines. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 1999;103:171-2.
• 2. Sutter RW, Suleiman AJ, Malankar P, Al-Khusaiby S, Mehta F, Clements GB et al. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 2000;343:767-73.
• 3. Wattigney WA, Mootrey GT, Braun MM, Chen RT. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics 2001;107:E83.
• 4. Plotkin SA, Vidor E. Poliovirus vaccine-Inactivated. In Plotkin SA. Orenstein WA. Vaccines. 4th edition. Philadelphia. WD Saunders, 2004;625-49.
• 5. WHO position paper on the introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Weekly Epidemiological Record 2003;78:241-52.
• 6. Niu MT, Rhodes P, Salive M, Lively T, Davis DM, Black S et al. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Events Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J Clin Epidemiol 1998;51:503-10.
• 7. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D et al. The Guillain-Barre syndrome and the 1992- 1993 and 1993-1994 infl uenza vaccines. N Engl J Med 1998;339:1797-802.
• 8. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine-United States, 1998- 1999. MMWR Morb Mortal Wkly Rep 1999;48:577-81.
• 9. Centers for Disease Control and Prevention: Chapter 8. Poliomyelitis. Epidemiology and Prevention of VaccinePreventable Diseases. The Pink Book.9th ed. 2006.
• 10. Plotkin S.A. and Orenstein W.A.(ed): Vaccines. 4th ed. W.B. Saunders Co., Philadelphia 2003.
• 11. Sugawara T, Ohsuka Y, Taya K, Yasui Y, Wada N, Sakano M et al. Diarrhea as a minor adverse effect due to oral polio vaccine. Jpn J Infect Dis 2009;62:51-3.
• 12. Manual for the virological investigation of polio. Geneva, World Health Organization, 1997; (unpublished document WHO/EPI/ GEN/97.01)
• 13. Kapoor A, Ayyagari A, Dhole TN. Non-polio enteroviruses in acute fl accid paralysis. Indian J Pediatr 2001;68:927-9.
• 14. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR et al. Vaccine Policy Changes and Epidemiology of Poliomyelitis in the United States. JAMA 2004;292:1696-704.
• 15. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol 1999;103:321-5.
• 16. Sakaguchi M, Nakayama T, Inouye S. Cases of systemic immediate-type utrticaria associated with acellular diphtheriatetanus-pertussis vaccination. Vaccine 1998;16:1138-40.